PE-backed CMO expands syringe filling capabilities

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/NikiLitov)
(Image: Getty/NikiLitov)
Grand River Aseptic Manufacturing (GRAM) has purchased a new syringe filler to help meet "the rising demand" for parenteral development and manufacturing services.

The Colanar FSV syringe filler will use the facility's existing single-use systems and will support both small molecule APIs and biologics projects at its FDA-inspected, cGMP-compliant manufacturing facility in Grand Rapids, MI.

The syringe filler – expected to be qualified and operational by the second quarter of 2018 – is also capable of handling cartridges, according to the parenteral contract manufacturing organization (CMO).

"GRAM purchased the syringe filler to support our client’s product growth,"​ Steve Nole, director of operations at GRAM, told us.

The company has also seen a significant increase in request for pre-filled syringes over the last six to 12 months, he said.

When asked how GRAM plans to continue investing to meet this demand, Nole explained the company is building a new facility that will include a new filling suite with a high-speed integrated fill line, "utilizing best-in-class isolator technology."

The new facility is expected to open in 2020.

GRAM recently announced an investment​ from the private equity (PE) firm Arlington Capital Partners. According to the company, the new funding will enable it to expand and add capacity to meet a “the rising demand”​ for parenteral development and manufacturing services.

Related news

Show more

Related products

show more

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more


View more